Investor Presentation • Apr 14, 2021
Investor Presentation
Open in ViewerOpens in native device viewer
Operational Update April 15, 2021
This presentation (the "Presentation") has been produced by Atlantic Sapphire ASA (the "Company") exclusively for information purposes. This Presentation has not been approved, reviewed or registered with any public authority or stock exchange. This Presentation is not a prospectus and does not contain the same level of information as a prospectus. This Presentation may not be disclosed, in whole or in part, or summarized or otherwise reproduced, distributed or referred to, in whole or in part, without prior written consent of the Company. To the best of the knowledge of the Company and its Board of Directors, the information contained in this Presentation is in all material respect in accordance with the facts as of the date hereof, and contains no material omissions likely to affect its import.
This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates or intends to operate. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. None of the Company or any of its subsidiary undertakings or any such person's officers or employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. The Company assumes no obligation to update any forward-looking statements or to conform these forward-looking statements to our actual results. Furthermore, information about past performance given in this Presentation is given for illustrative purposes only and should not be relied upon as, and is not, an indication of future performance. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the Company nor any of its parent or subsidiary undertakings or any such person's officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. Actual experience may differ, and those differences can be material.
By reviewing this Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the businesses of the Company. This Presentation must be read in conjunction with the recent financial reports of the Company and the disclosures therein. The distribution of this Presentation in certain jurisdictions may be restricted by law. Persons in possession of this Presentation are required to inform themselves about, and to observe, any such restrictions. No action has been taken or will be taken in any jurisdiction by the Company that would permit the possession or distribution of this Presentation in any country or jurisdiction where specific action for that purpose is required.
No shares or other securities are being offered pursuant to this Presentation. This Presentation does not constitute an offer to sell or form part of, and should not be construed as, an offer or invitation for the sale or subscription of, or a solicitation of an offer to buy or subscribe for, any shares or other securities in any jurisdiction, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.
By reviewing this Presentation you agree to be bound by the foregoing limitations.
This Presentation speaks as of April 14, 2021. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation. This Presentation shall be governed by Norwegian law, and any disputes relating to hereto is subject to the sole and exclusive jurisdiction of Norwegian courts, with Oslo District Court as legal venue.
| Three months ending Mar 31, 2021 | US | DK |
|---|---|---|
| Net revenue per kg of total harvest (HOG) | USD6.8/kg | DKK37/kg |
| Net revenue per kg for Sup 3kg+ (HOG) | ~USD12/kg | ~DKK41/kg |
| Bluehouse Salmon (Sup 3kg+) premium to Fish Pool commodity1 | 90% | 6% |
| Net biomass gain (RLW)2 | ~(300)t | ~150t |
| Harvest volume (HOG) | 421t | 300t |
▪ US blended price achievement and biomass gain impacted by the "frontrunners" in Batch 1 having a lower superior share
Premium Price Achievement Established In The US, Poor Quarter Due To Operational Challenges.
1 Fish Pool spot index (Superior 3kg+) average salmon price for Q1 2021: EUR5.22/kg HOG (not volume weighted) or around USD6.3/kg HOG 2 Net biomass gain estimate based on combination of actual feeding figures and management estimates, and includes ordinary and extraordinary mortality 3 Feed Conversion Ratio (FCR)
| US Q1 2021 challenges | Why it's important | What's been the Q1 impact | When it will be fixed |
|---|---|---|---|
| New center drain (design weakness) |
Avoids clogging of tanks; ensures stable flow of new water into tanks even in case of elevated mortality. |
Resulted in March 23 mortality event, XXX because the new drains had not yet been installed |
Q2 2021 |
| Splitting of growout systems |
Risk mitigation; reduce financial impact of incidents |
Higher financial impact of March 23 mortality event |
Q2 2021 |
| Internal chiller plant breakdown |
Temperature stability and cost of cooling | Temporary temperature instability and rental chillers and generators add short term cost |
Electrified by Q2 2021, cutting chilling cost |
| Drum filter area, ozone and protein skimmers not fully commissioned |
Water quality optimization tools necessary to reach budgeted feeding |
Reduced Q1 2021 feeding and growth, poor drum sump design triggered March 23 incident |
Q2 2021 |
| Batch 1 maturation | Reduced growth, high FCR and lower price achievement |
Low biological performace and price achievement in Q4(20) & Q1(21) |
Currently, normal maturation for Batch 2 |
▪ Construction and commissioning-related issues caused suboptimal conditions, reduced growth and increased cost in Q1 2021
▪ As seen in Q4 2020 and parts of Q1 2021, the systems deliver JEA Index in line with budget when fully operational and stable
Action Plan Implemented For All Known Issues To Get Back Target To JEA Index
Phase 1 Completion Has Taken More Time. Focus Shifting To Phase 2 Construction.
1 Includes 12 independent growout systems and seven freshwater systems
US phase 2 Bluehouse site cleared
Atlantic Sapphire's First Integrated ESG and Annual Report Is Now Published
| Year ended 31 December 2020 (USD 1,000) |
Fish farming | |||
|---|---|---|---|---|
| Denmark | USA | Other and eliminations |
Consolidated | |
| Revenue from sale of salmon | 5,041 | 1,729 | (500) | 6,270 |
| EBITDA | (8, 111) | (30, 645) | (1,094) | (39, 850) |
| EBITDA, pre-fair value adjustment on biological assets | (6, 355) | (22, 923) | (1,094) | (30, 372) |
| Pre-tax loss | (12, 465) | (45, 071) | 2,343 | (55, 193) |
| Total assets | 44,868 | 259,888 | 16,203 | 320,959 |
| Total liabilities | 36,600 | 141,759 | (112, 859) | 65,500 |
| Depreciation and amortization | 2,563 | 4,182 | $\rightarrow$ | 6,745 |
| Capital expenditures | 2,514 | 52,041 | $\overline{\phantom{m}}$ | 54,555 |
| Cash flows from operating activities | (7,693) | (41,038) | 1,772 | (46, 959) |
| Cash flows from investing activities | (2, 810) | (58, 047) | 6 | (60, 851) |
| Cash flows from financing activities | 9,551 | 92,659 | 9,754 | 111,964 |
|
11
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.